Altimmune, Inc. (ALT) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Altimmune (ALT) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Altimmune is a clinical-stage biopharmaceutical company whose value rests almost entirely on pemvidutide, a GLP-1/glucagon dual agonist being developed for obesity and MASH (a serious fatty-liver disease). The single biggest risk is that outcomes are binary: a Phase 3 miss or regulatory setback could sharply reduce the stock, since the company has no approved product or product revenue. As of October 16, 2026 the shares closed near $2.30, down about 35% year to date and sitting at their 52-week low, for a market cap of roughly $446 million, below the company's reported cash and investments.
ALT stock price
As of 2026-11-16, Altimmune, Inc. (ALT) last closed at $1.56, down 62.8% over the past year. Over the past 52 weeks it has traded between $1.56 and $6.18.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Altimmune, Inc.'s investor relations page. Walnut is informational, not investment advice.
ALT key stats
At $1.56 on November 16, 2026, Altimmune, Inc. (ALT) has a market cap of $303M.
- Market cap
- $303M
- Price to book
- 0.6
- Beta
- 0.15
Market cap, P/E and yield are measured at the $1.56 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Altimmune, Inc. (ALT)?
The last two weeks for Altimmune, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ALT closed at $1.56 on November 16, 2026, down 26.4% over the past five trading days (from $2.12).
- On November 12, 2026, Altimmune, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 12, 2026, Altimmune, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Altimmune, Inc. (ALT) do?
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo. On the strength of IMPACT, pemvidutide received FDA Breakthrough Therapy Designation in MASH.
2026 turned pemvidutide into a liver-disease franchise with three trials running at once. In August the company started PERFORMA, a global Phase 3 MASH trial whose 52-week readout is not expected until 2029. In July, the Phase 2 RECLAIM trial in alcohol use disorder hit its primary endpoint and won FDA Fast Track designation, with an End-of-Phase 2 meeting to be requested, and the Phase 2 RESTORE trial in alcohol-associated liver disease finished enrollment, with topline data due in the second half of 2027.
The company generates no product revenue and funds itself through cash raised in the capital markets, including a roughly $225 million offering in April 2026; cash and investments stood at about $519 million at June 30, 2026. The Q2 loss of about $0.12 a share matched estimates. The stock has not followed the clinical progress: as of October 16, 2026 it closed near $2.30, down about 35% year to date, about 41% over one year and about 29% over the past month, leaving a market cap near $446 million that is below the cash balance. As a single-asset, pre-commercial biotech, Altimmune's prospects hinge on clinical readouts, regulatory decisions, its cash runway, and whether it can differentiate in a GLP-1 market dominated by much larger competitors.
What's driving Altimmune, Inc. (ALT)?
Differentiated GLP-1/glucagon profile
Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. In the IMPACT MASH trial, the 1.8 mg dose showed about 7.5% weight loss alongside large reductions in liver fat.
MASH opportunity
The Phase 2b IMPACT trial hit key 48-week measures, with statistically significant improvements in noninvasive fibrosis markers versus placebo, earning Breakthrough Therapy Designation. The Phase 3 PERFORMA trial began in August 2026, though its 52-week data are not expected until 2029, a long wait with no late-stage MASH readout in between. MASH is a large, newly addressable market with few approved therapies.
Large obesity market
The GLP-1 obesity market is enormous and still expanding, so even a modest share for a differentiated entrant could be valuable. Pemvidutide targets both obesity and MASH, giving Altimmune two shots on goal from one molecule.
Alcohol use disorder and alcohol-related liver disease
Pemvidutide's second and third liver indications moved faster in 2026. The RECLAIM Phase 2 trial in alcohol use disorder met its primary endpoint in July and gained FDA Fast Track designation, and the RESTORE Phase 2 trial in alcohol-associated liver disease completed enrollment, with topline data due in the second half of 2027. These are the nearer-term catalysts while the MASH Phase 3 runs.
Funded for near-term milestones
Altimmune reported about $519 million in cash and investments at June 30, 2026, helped by a roughly $225 million April offering, against a quarterly net loss of about $23 million. That is a substantial runway for a company of 57 employees, though Phase 3 spending will rise and the company has not published a runway estimate.
What are the risks to Altimmune, Inc. (ALT)?
Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders; the April 2026 offering already did so. The share price has fallen to its 52-week low even as the trials advanced, which shows how little near-term support clinical milestones have given the stock.
What is the Altimmune, Inc. (ALT) forecast?
9 analysts publish price targets on ALT, averaging $17.11 as of November 2026, or +996.8% against the $1.56 share price on November 16, 2026. The published targets run from $11.00 to $28.00, a wide spread, and the ratings split 9 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ALT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ALT a buy or a sell?
We give no verdict on Altimmune, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Differentiated GLP-1/glucagon profile. Pemvidutide is designed to deliver meaningful weight loss while preserving lean muscle mass, a profile management argues could differentiate it from pure GLP-1 agonists. The most optimistic published target, $28.00, assumes this works close to its best case.
The case against. Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. The most pessimistic target, $11.00, is roughly what ALT is worth if this bites instead.
Read the full bull and bear case on ALT, including what would have to change to break either one. Walnut is not an investment adviser.
Has Altimmune, Inc. (ALT) split its stock?
Yes. Altimmune, Inc. (ALT) has had one share split in the last 10 years:
- 1:30 on September 14, 2018, so every share held became 0.03333333333333333 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of ALT the day before the 1:30 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Altimmune, Inc. (ALT) valued?
Market cap, P/E and dividend yield at today's price are in the ALT key stats above. The business figures below come from Altimmune, Inc.'s reported results as of October 2026 and change when it next reports.
- Product revenue: None (clinical-stage)
- Cash and investments (Jun 30, 2026): ~$519 million
- Net loss (TTM): ~$92 million
- MASH stage: Phase 3 (PERFORMA) started Aug 2026, data 2029
As of October 2026: As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. At about $446 million the market cap now sits below the roughly $519 million of cash and investments and under book value, which means the market is assigning little or negative value to the pipeline despite Breakthrough and Fast Track designations. Nine analysts carry a mean target near $17, far above the price, and the next quarterly report is expected around November 5, 2026.
Who competes with Altimmune, Inc. (ALT)?
GLP-1 obesity leaders
Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) dominate the obesity market with approved, blockbuster drugs and far larger resources than Altimmune.
Obesity and MASH biotechs
Companies such as Viking Therapeutics, Madrigal Pharmaceuticals (approved MASH drug), and other metabolic-disease developers compete for the same indications and investor attention.
Emerging dual/triple agonists
A growing field of next-generation GLP-1-based combination agonists from both large pharma and biotech raises the competitive bar for differentiation.
What stocks are similar to Altimmune, Inc. (ALT)?
Other names that sit close to ALT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Altimmune, Inc. (ALT)
There are three common ways to get ALT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALT sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ALT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Altimmune, Inc. (ALT)
Altimmune is a one-asset story: pemvidutide's data in MASH, alcohol-related liver disease and obesity determines almost everything, and the Phase 3 MASH readout is not expected until 2029. If you believe its weight-loss-plus-liver profile can carve out a niche against far larger GLP-1 rivals, the question becomes how much binary clinical risk you want and how to size it, not timing. The risk is that a single failed trial or a financing crunch can erase much of the value, and the company competes against Novo Nordisk and Eli Lilly with a fraction of their resources.
More on Altimmune, Inc. (ALT)
Whether ALT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALT a buy or a sell?, and where the stock could go from here in the ALT stock forecast.
For income investors, whether ALT pays a dividend and how the payout looks is covered in does ALT pay a dividend? And to weigh ALT against a peer, read the full side-by-side comparisons: ALT vs NVO and ALT vs LLY.
Wondering how ALT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Altimmune, Inc.
Ask Walnut's AI anything about ALT and see how it fits what you own.
FAQ
Is ALT a good stock to buy right now?
+
It depends on your risk tolerance. Bulls cite positive Phase 2b MASH data, a positive Phase 2 alcohol use disorder trial, Breakthrough and Fast Track designations, and a cash position larger than the market cap. Bears note it is a single-asset, pre-revenue biotech whose Phase 3 MASH data are not due until 2029 and that it faces giant competitors. ALT suits investors who accept high volatility and possible total loss, not conservative buyers. This is not investment advice, and Walnut is not an investment adviser.
What does Altimmune do?
+
Altimmune is a clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual agonist, for obesity and MASH (metabolic dysfunction-associated steatohepatitis, a serious fatty-liver disease). It has no approved products and is focused on advancing pemvidutide through clinical trials toward potential regulatory approval.
What is pemvidutide?
+
Pemvidutide is Altimmune's lead drug candidate, a once-weekly injectable that activates both the GLP-1 and glucagon receptors. It is designed to produce weight loss while preserving lean muscle mass and improving liver health, and is being studied in both obesity and MASH, where it reported positive Phase 2b results.
Is ALT profitable?
+
No. Altimmune is a clinical-stage company with no approved products and no product revenue, so it operates at a loss, about $92 million over the trailing twelve months, as it funds research and development. It relies on its cash and investments, about $519 million at June 30, 2026, and may raise additional capital to fund pemvidutide's lengthy and costly development.
Does ALT pay a dividend?
+
No. Altimmune does not pay a dividend. Like most clinical-stage biotech companies, it reinvests all available capital into drug development and preserves cash to fund trials, so any return to shareholders would come only from share-price appreciation, not income.
What are the next catalysts for ALT?
+
The PERFORMA Phase 3 MASH trial began in August 2026, but its 52-week readout is not expected until 2029. Nearer-term events include an End-of-Phase 2 meeting with the FDA on alcohol use disorder, topline RESTORE data in alcohol-associated liver disease in the second half of 2027, the Q3 report expected around November 5, 2026, and any partnership news.
Who are Altimmune's competitors?
+
In obesity, Altimmune competes with GLP-1 leaders Novo Nordisk and Eli Lilly, plus biotechs like Viking Therapeutics. In MASH, Madrigal Pharmaceuticals already has an approved therapy. The field is crowded and well-funded, which raises the bar for pemvidutide to stand out.
Why is ALT stock so volatile?
+
Altimmune's value depends almost entirely on pemvidutide's clinical and regulatory progress, so the stock swings sharply on trial data, conference presentations, and competitor news. Single-asset, pre-revenue biotechs are inherently volatile because each readout can dramatically change the company's prospects.
How has ALT stock performed in 2026?
+
As of the October 16, 2026 close near $2.30, ALT was down about 35% year to date, about 41% over one year and about 29% over the past month, ending the day at its 52-week low. The 52-week high was $6.44.
What happened in Altimmune's alcohol use disorder trial?
+
The Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder hit its primary endpoint in July 2026, and the FDA granted Fast Track designation. Altimmune plans to request an End-of-Phase 2 meeting with the FDA to discuss next steps.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Altimmune, Inc.'s investor relations page or your broker before making investment decisions.